DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta-burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

The Department of Veterans' Affairs commissioned Ernst & Young to conduct a review of better practice approaches in the evaluation of health and wellbeing programs. The aim of the review was to provide recommendations regarding the existing types of evaluation occurring within health programs across Australia (e.g. process, impact, economic/value for money, fidelity, outcome), including the appropriate use of each type of evaluation. These recommendations help inform how the department can plan for and carry out evaluations to support the wellbeing of veterans and families.